Neogenomics, Inc.
NEO
$7.42
$0.294.07%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | 672.36M | 660.57M | 644.12M | 628.25M | 610.66M |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 672.36M | 660.57M | 644.12M | 628.25M | 610.66M |
Cost of Revenue | 374.48M | 370.47M | 363.69M | 360.39M | 355.40M |
Gross Profit | 297.88M | 290.10M | 280.43M | 267.86M | 255.26M |
SG&A Expenses | 342.35M | 337.48M | 329.91M | 327.74M | 321.94M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 750.56M | 739.10M | 723.92M | 716.04M | 704.88M |
Operating Income | -78.19M | -78.54M | -79.80M | -87.79M | -94.22M |
Income Before Tax | -78.65M | -80.68M | -79.83M | -83.44M | -91.06M |
Income Tax Expenses | -1.06M | -1.95M | -2.11M | -4.89M | -6.82M |
Earnings from Continuing Operations | -77.59 | -78.73 | -77.73 | -78.55 | -84.23 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -77.59M | -78.73M | -77.73M | -78.55M | -84.23M |
EBIT | -78.19M | -78.54M | -79.80M | -87.79M | -94.22M |
EBITDA | -6.19M | -5.99M | -7.08M | -14.93M | -21.20M |
EPS Basic | -0.61 | -0.62 | -0.62 | -0.62 | -0.67 |
Normalized Basic EPS | -0.33 | -0.33 | -0.33 | -0.38 | -0.41 |
EPS Diluted | -0.61 | -0.63 | -0.62 | -0.63 | -0.67 |
Normalized Diluted EPS | -0.33 | -0.33 | -0.33 | -0.38 | -0.41 |
Average Basic Shares Outstanding | 507.89M | 506.63M | 505.40M | 504.13M | 503.08M |
Average Diluted Shares Outstanding | 507.89M | 506.63M | 505.40M | 504.13M | 503.08M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |